Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorXijing Hospital
About this trial
This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.
Eligibility criteria
Qualifiers
Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.
Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle cerebral artery.
A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.
Pre-stroke mRS score is ≤1.
Disqualifiers
Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.;
Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys;
Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;
Head CT/MRI suggests acute cerebral infarction in both sides;
Trial design
Treatments tested in this trial
- Transcranial Magnetic Stimulation Active
- Transcranial Magnetic Stimulation Sham
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov